Therapies for triple negative breast cancer

Eleni Andreopoulou, Sarah J. Schweber, Joseph A. Sparano, Hayley M. McDaid

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly sensitive to platinums and/or inhibitors of poly(ADP-ribose)polymerase. A substantial proportion of patients with TNBCs not associated with germ-line BRCA mutations may have tumors that are 'BRCA-like', rendering those individuals potential candidates for similar strategies.Areas covered: The purpose of this review is to highlight the current standard and experimental treatment strategies.Expert opinion: Recent research that has illuminated the molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to chemotherapy. Modern technology platforms provide molecular signatures that can be mined for therapeatic interventions. Target pathways that are commonly dysregulated in cancer cells control cellular processes such as apoptosis, proliferation, angiogenesis, DNA repair, cell cycle progression, immune modulation and invasion, and metastasis. Novel trial design and re-defined endpoints as surrogates to clinical outcome have been introduced to expedite the development of breakthrough therapies to treat high-risk early-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)983-998
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number7
DOIs
StatePublished - May 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Germ-Line Mutation
Biomarkers
Neoplasms
Expert Testimony
Therapeutics
DNA Repair
Cell Cycle
Apoptosis
Breast Neoplasms
Neoplasm Metastasis
Technology
Recurrence
Drug Therapy
Research

Keywords

  • Basal-like breast cancer
  • BRCA mutations
  • Phosphatidylinositide 3-kinase pathway
  • Platinums
  • Poly(ADP-ribose)polymerase inhibitor
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Therapies for triple negative breast cancer. / Andreopoulou, Eleni; Schweber, Sarah J.; Sparano, Joseph A.; McDaid, Hayley M.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 7, 01.05.2015, p. 983-998.

Research output: Contribution to journalArticle

Andreopoulou, Eleni ; Schweber, Sarah J. ; Sparano, Joseph A. ; McDaid, Hayley M. / Therapies for triple negative breast cancer. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 7. pp. 983-998.
@article{02d2537abf3349faa7614a610c575518,
title = "Therapies for triple negative breast cancer",
abstract = "Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20{\%} of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly sensitive to platinums and/or inhibitors of poly(ADP-ribose)polymerase. A substantial proportion of patients with TNBCs not associated with germ-line BRCA mutations may have tumors that are 'BRCA-like', rendering those individuals potential candidates for similar strategies.Areas covered: The purpose of this review is to highlight the current standard and experimental treatment strategies.Expert opinion: Recent research that has illuminated the molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to chemotherapy. Modern technology platforms provide molecular signatures that can be mined for therapeatic interventions. Target pathways that are commonly dysregulated in cancer cells control cellular processes such as apoptosis, proliferation, angiogenesis, DNA repair, cell cycle progression, immune modulation and invasion, and metastasis. Novel trial design and re-defined endpoints as surrogates to clinical outcome have been introduced to expedite the development of breakthrough therapies to treat high-risk early-stage breast cancer.",
keywords = "Basal-like breast cancer, BRCA mutations, Phosphatidylinositide 3-kinase pathway, Platinums, Poly(ADP-ribose)polymerase inhibitor, Triple negative breast cancer",
author = "Eleni Andreopoulou and Schweber, {Sarah J.} and Sparano, {Joseph A.} and McDaid, {Hayley M.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1517/14656566.2015.1032246",
language = "English (US)",
volume = "16",
pages = "983--998",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Therapies for triple negative breast cancer

AU - Andreopoulou, Eleni

AU - Schweber, Sarah J.

AU - Sparano, Joseph A.

AU - McDaid, Hayley M.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly sensitive to platinums and/or inhibitors of poly(ADP-ribose)polymerase. A substantial proportion of patients with TNBCs not associated with germ-line BRCA mutations may have tumors that are 'BRCA-like', rendering those individuals potential candidates for similar strategies.Areas covered: The purpose of this review is to highlight the current standard and experimental treatment strategies.Expert opinion: Recent research that has illuminated the molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to chemotherapy. Modern technology platforms provide molecular signatures that can be mined for therapeatic interventions. Target pathways that are commonly dysregulated in cancer cells control cellular processes such as apoptosis, proliferation, angiogenesis, DNA repair, cell cycle progression, immune modulation and invasion, and metastasis. Novel trial design and re-defined endpoints as surrogates to clinical outcome have been introduced to expedite the development of breakthrough therapies to treat high-risk early-stage breast cancer.

AB - Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly sensitive to platinums and/or inhibitors of poly(ADP-ribose)polymerase. A substantial proportion of patients with TNBCs not associated with germ-line BRCA mutations may have tumors that are 'BRCA-like', rendering those individuals potential candidates for similar strategies.Areas covered: The purpose of this review is to highlight the current standard and experimental treatment strategies.Expert opinion: Recent research that has illuminated the molecular heterogeneity of the disease rationalizes its diverse biological behavior and differential response to chemotherapy. Modern technology platforms provide molecular signatures that can be mined for therapeatic interventions. Target pathways that are commonly dysregulated in cancer cells control cellular processes such as apoptosis, proliferation, angiogenesis, DNA repair, cell cycle progression, immune modulation and invasion, and metastasis. Novel trial design and re-defined endpoints as surrogates to clinical outcome have been introduced to expedite the development of breakthrough therapies to treat high-risk early-stage breast cancer.

KW - Basal-like breast cancer

KW - BRCA mutations

KW - Phosphatidylinositide 3-kinase pathway

KW - Platinums

KW - Poly(ADP-ribose)polymerase inhibitor

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84928521991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928521991&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1032246

DO - 10.1517/14656566.2015.1032246

M3 - Article

C2 - 25881743

AN - SCOPUS:84928521991

VL - 16

SP - 983

EP - 998

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -